I have been throught quite a few shortie rodeos..and this is playing itself out like a script. Amazing to watch really. The short thesis is comprised largely of Concordia &/or the pharma business/political environment, "may do this or that bad thing in the future", to create FUD. Unlike Valiant, there is no whistleblower here that was connected to a major short seller, that disclosed a pharmacy chain (worth 17% of Valiants sales) was providing preferential dispensing to the suppliers up charged drugs. Here at Concordia, the financial statements, in-line product sales, new product launches suggest the company will remain a going concern far into the future. Seeking Alpo and other redundant articles provide little new reason to buy or sell. The SP is amazingly low with consistent fundamentals so it's a buy signal for me. The only question I am wondering is how low this can go, and how long the shortie can keep it down. The earnings is not a binary event like others are making it out to be, it will simply be a one in a series of quarterly earnings that will show things are moving along nicely in the long term.